A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study

References

• World Health Organization (WHO). Archived: WHO timeline—COVID-19. https://www.who.int/news/item/27-04-2020-who-timeline---covid-19. Accessed 5 May 2022.
   Google Scholar
• Weekly epidemiological update on COVID-19—22 February 2022. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-february-2022. Accessed 27 Apr 2022.
   Google Scholar
• El-Shitany NA, Harakeh S, Badr-Eldin SM, Bagher AM, Eid B, Almukadi H, et al.Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: a retrospective cross-sectional studyIJGM20211413891401 10.2147/IJGM.S310497
   Google Scholar
• Jeon M, Kim J, Oh CE, Lee JYAdverse events following immunization associated with coronavirus disease 2019 vaccination reported in the mobile vaccine adverse events reporting systemJ Korean Med Sci20213617 1:CAS:528:DC%2BB3MXhs1WjsbbF 10.3346/jkms.2021.36.e114 33942578 8093606
   PubMed Web of Science ®Google Scholar
• Le Thanh T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al.The COVID-19 vaccine development landscapeNat Rev Drug Discov2020195305306 10.1038/d41573-020-00073-5
   PubMed Web of Science ®Google Scholar
• Mascellino MT, Di Timoteo F, De Angelis M, Oliva AOverview of the main anti-SARS-CoV-2 vaccines: mechanism of actionEffic Saf Infect Drug Resist20211434593476 10.2147/IDR.S315727
   PubMed Web of Science ®Google Scholar
• Ghasemiyeh P, Mohammadi-Samani S, Firouzabadi N, Dehshahri A, Vazin AA focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccinesInt Immunopharmacol2021100 1:CAS:528:DC%2BB3MXitVyrtLbO 10.1016/j.intimp.2021.108162 34562844 8445802
   PubMed Web of Science ®Google Scholar
• Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al.Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control studyBMJ2021373 10.1136/bmj.n1088
   Google Scholar
• Minister Office. Minister Hasan announces first coronavirus case in Lebanon. 2020. http://www.moph.gov.lb. Accessed 5 May 2022.
   Google Scholar
• Lebanon: the latest coronavirus counts, charts and maps. Reuters. https://graphics.reuters.com/world-coronavirus-tracker-and-maps/countries-and-territories/lebanon/. Accessed 5 May 2022.
   Google Scholar
• Gee JFirst month of COVID-19 vaccine safety monitoring—United States, December 14, 2020–January 13, 2021MMWR Morb Mortal Wkly Rep202170283 1:CAS:528:DC%2BB3MXnt1Wrur0%3D 10.15585/mmwr.mm7008e3 33630816 8344985
   PubMed Web of Science ®Google Scholar
• COVID-19 vaccination campaigns launched across Europe. https://www.aa.com.tr/en/europe/covid-19-vaccination-campaigns-launched-across-europe/2090420. Accessed 27 Apr 2022.
   Google Scholar
• COVID-19 Vaccine National Coordinating Committee. Lebanon national deployment and vaccination plan for COVID-19 vaccines. Republic of Lebanon Ministry of Public Health. https://www.moph.gov.lb/userfiles/files/Prevention/COVID-19%20Vaccine/Lebanon%20NDVP-%20Feb%2016%202021.pdf.
   Google Scholar
• Organisation mondiale de la santéDefinition and application of terms for vaccine pharmacovigilance: report of CIOMS-WHO working group on vaccine pharmacovigilance2012GenevaWorld health organization
   Google Scholar
• Paczkowska A, Hoffmann K, Michalak M, Hans-Wytrychowska A, Bryl W, Kopciuch D, et al.Safety profile of COVID-19 vaccines among healthcare workers in PolandVaccines2022103434 1:CAS:528:DC%2BB38XovVGgtLs%3D 10.3390/vaccines10030434 35335066 8949184
   PubMed Web of Science ®Google Scholar
• Oster ME, Shay DK, Su JR, et al.Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021JAMA20223274331340 1:CAS:528:DC%2BB38XisFSiu7k%3D 10.1001/jama.2021.24110 35076665 8790664
   PubMed Web of Science ®Google Scholar
• Wan EYF, Chui CSL, Lai FTT, Chan EWY, Li X, Yan VKC, et al.Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control studyLancet Infect Dis20222216472 1:CAS:528:DC%2BB3MXhvVemurrO 10.1016/S1473-3099(21)00451-5 34411532
   PubMed Web of Science ®Google Scholar
• Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021 | Vaccination | JAMA | JAMA Network. https://jamanetwork.com/journals/jama/fullarticle/2788346. Accessed 27 Apr 2022.
   Google Scholar
• Carli G, Nichele I, Ruggeri M, Barra S, Tosetto ADeep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccineIntern Emerg Med2021163803804 10.1007/s11739-021-02685-0 33687691 7940863
   PubMed Web of Science ®Google Scholar
• Shimabukuro T, Nair NAllergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccineJAMA20213258780781 1:CAS:528:DC%2BB3MXlt1GjsbY%3D 10.1001/jama.2021.0600 33475702 8892260
   PubMed Web of Science ®Google Scholar
• Gorman JM, Gorman SE, Sandy W, Gregorian N, Scales DAImplications of COVID-19 vaccine hesitancy: results of online bulletin board interviewsFront Public Health20229 10.3389/fpubh.2021.757283 35111712 8802137
   PubMed Web of Science ®Google Scholar
• Republic of Lebanon Ministry of Public Health. Ministry of public health: calling 1214 and 1787 became free of charge. http://www.refugees-lebanon.org/uploads/poster/poster_161728344494.pdf.
   Google Scholar
• IMPACT. https://covax.moph.gov.lb/impactmobile/vaccine. Accessed 5 May 2022.
   Google Scholar
• Impact Open Data. https://impact.cib.gov.lb/home. Accessed 9 May 2022.
   Google Scholar
• Detailed format for AEFI on site of vaccination/health facility. https://ee.kobotoolbox.org/x/um9QwK2N. Accessed 5 May 2022.
   Google Scholar
• World Health Organization. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification, 2nd edition, 2019 update. Geneva: World Health Organization; 2019. https://apps.who.int/iris/handle/10665/340802. Accessed 14 Apr 2022.
   Google Scholar
• Aboka D. VigiFlow, introduction and basic features. Uppsala Monitoring Centre. https://who-umc.org/media/165665/1-introduction-and-basic-features-of-vigiflow.pdf.
   Google Scholar
• VigiFlow. https://vigiflow.who-umc.org/searchicsrs.
   Google Scholar
• AEFI investigation form. https://www.who.int/publications/m/item/aefi-investigation-form. Accessed 27 Apr 2022.
   Google Scholar
• AEFI : causality assessment software. http://gvsi-aefi-tools.org/. Accessed 27 Apr 2022.
   Google Scholar
• Republic of Lebanon Ministry of Public Health. Memo 603–2021, serious adverse events following immunization AEFIs. https://www.moph.gov.lb/userfiles/files/Laws%26Regulations/Karar%20603-2021.pdf.
   Google Scholar
• World Health Organaziation-Uppsala Monitoring Centre (WHO-UMC). VigiLyze. https://vigilyze.who-umc.org/.
   Google Scholar
• Uppsala Monitoring Centre. Your window to a world of global safety insights. https://who-umc.org/pv-products/vigilyze/.
   Google Scholar
• Republic of Lebanon Ministry of Public Health. COVID-19 coronavirus Lebanon cases. https://www.moph.gov.lb/maps/covid19.php.
   Google Scholar
• Sallam MCOVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance ratesVaccines202192160 1:CAS:528:DC%2BB3MXitVSmu7fL 10.3390/vaccines9020160 33669441 7920465
   PubMed Web of Science ®Google Scholar
• Hanna P, Issa A, Noujeim Z, Hleyhel M, Saleh NAssessment of COVID-19 vaccines acceptance in the Lebanese population: a national cross-sectional studyJ Pharm Policy Pract20221515 10.1186/s40545-021-00403-x 35016705 8749113
   PubMed Web of Science ®Google Scholar
• Joshi RK, Muralidharan CG, Gulati DS, Mopagar V, Dev JKP, Kuthe S, et al.Higher incidence of reported adverse events following immunisation (AEFI) after first dose of COVID-19 vaccine among previously infected health care workersMed J Armed Forces India202177Suppl 2S505S507 10.1016/j.mjafi.2021.05.011 34334920 8313055
   PubMedGoogle Scholar
• Tran VN, Nguyen HA, Le TTA, Truong TT, Nguyen PT, Nguyen TTHFactors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021Vaccine2021394464856491 1:CAS:528:DC%2BB3MXitFOltrzK 10.1016/j.vaccine.2021.09.060 34607748 8485226
   PubMed Web of Science ®Google Scholar
• Side effects reported by Jordanian healthcare workers who received COVID-19 vaccines. https://pubmed.ncbi.nlm.nih.gov/34205917/. Accessed 29 Apr 2022.
   Google Scholar
• McCartney PRSex-based vaccine response in the context of COVID-19J Obstet Gynecol Neonatal Nurs2020495405408 10.1016/j.jogn.2020.08.001 32800743 7405769
   PubMed Web of Science ®Google Scholar
• Azimi M, Dehzad WM, Atiq MA, Bahain B, Asady AAdverse effects of the COVID-19 vaccine reported by lecturers and staff of Kabul University of Medical Sciences, Kabul, AfghanistanInfect Drug Resist20211440774083 10.2147/IDR.S332354 34629882 8494987
   PubMed Web of Science ®Google Scholar
• Adverse events following immunization monitoring-Covid-19 vaccines-Lebanon. https://www.moph.gov.lb/en/Pages/4/44742/. Accessed 29 Apr 2022.
   Google Scholar
• Ontario Agency for Health Protection and Promotion (Public Health Ontario). Adverse events following immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to April 10, 2022. https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-aefi-report.pdf?sc_lang=en.
   Google Scholar
• Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al.Analysis of COVID-19 vaccine type and adverse effects following vaccinationJAMA Netw Open2021412 10.1001/jamanetworkopen.2021.40364 34935921 8696570
   PubMed Web of Science ®Google Scholar
• AlKhamesAga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batineh Y, Dahham AT, et al.Safety of COVID-19 vaccinesJ Med Virol2021931265886594 1:CAS:528:DC%2BB3MXhs1Gru7rL 10.1002/jmv.27214
   PubMed Web of Science ®Google Scholar
• Hause AMSafety monitoring of an additional dose of COVID-19 vaccine—United States, August 12–September 19, 2021MMWR Morb Mortal Wkly Rep2021701379 1:CAS:528:DC%2BB3MXisVKgsr3L 10.15585/mmwr.mm7039e4 34591835 8486391
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccineN Engl J Med20203832726032615 1:CAS:528:DC%2BB3MXotFSjuw%3D%3D 10.1056/NEJMoa2034577 33301246
   PubMed Web of Science ®Google Scholar
• Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al.Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adultsN Engl J Med20203832524272438 1:CAS:528:DC%2BB3cXis1yksL3E 10.1056/NEJMoa2028436 32991794
   PubMed Web of Science ®Google Scholar
• Andrzejczak-Grządko S, Czudy Z, Donderska MSide effects after COVID-19 vaccinations among residents of PolandEur Rev Med Pharmacol Sci2021251244184421 34227078
   PubMed Web of Science ®Google Scholar
• Wong CKH, Xiong X, Lau KTK, Chui CSL, Lai FTT, Li X, et al.Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalizationBMC Med2022201119 1:CAS:528:DC%2BB38XnsFCmu7g%3D 10.1186/s12916-022-02321-4 35296305 8926447
   PubMed Web of Science ®Google Scholar
• Sah R, Shrestha S, Mehta R, Sah SK, Rabaan AA, Dhama K, et al.AZD1222 (Covishield) vaccination for COVID-19: experiences, challenges, and solutions in NepalTravel Med Infect Dis202140 1:CAS:528:DC%2BB38XhsFWhs77E 10.1016/j.tmaid.2021.101989 33578045 7872846
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al.Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKLancet20213971026999111 1:CAS:528:DC%2BB3cXisFCgt77I 10.1016/S0140-6736(20)32661-1 33306989 7723445
   PubMed Web of Science ®Google Scholar
• Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, et al.Evaluation of the safety profile of COVID-19 vaccines: a rapid reviewBMC Med202119173 1:CAS:528:DC%2BB3MXhs1OhtrjM 10.1186/s12916-021-02059-5 34315454 8315897
   PubMed Web of Science ®Google Scholar
• Information for UK recipients on COVID-19 vaccine AstraZeneca (Regulation 174). GOV.UK. https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-uk-recipients-on-covid-19-vaccine-astrazeneca. Accessed 29 Apr 2022.
   Google Scholar
• Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, et al.Guillain–Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977Am J Epidemiol19791102105123 1:STN:280:DyaE1M3ivV2rsw%3D%3D 10.1093/oxfordjournals.aje.a112795 463869
   PubMed Web of Science ®Google Scholar
• Hanson KE, Goddard K, Lewis N, Fireman B, Myers TR, Bakshi N, et al.Guillain–Barré syndrome after COVID-19 vaccination in the vaccine safety datalinkmedRxiv2021 10.1101/2021.12.03.21266419v1 34426817 8382134
   PubMedGoogle Scholar
• EMA. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low platelets. European Medicines Agency. 2021. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood. Accessed 29 Apr 2022.
   Google Scholar
• Chan B, Odutayo A, Juni P, Stall NM, Bobos P, Brown AD, et al. Risk of vaccine-induced thrombotic thrombocytopenia (VITT) following the AstraZeneca/COVISHIELD adenovirus vector COVID-19 vaccines. Ontario COVID-19 Science Advisory Table; 2021. https://covid19-sciencetable.ca/sciencebrief/risk-of-vaccine-induced-thrombotic-thrombocytopenia-vitt-following-the-astrazeneca-covishield-adenovirus-vector-covid-19-vaccines/. Accessed 29 Apr 2022.
   Google Scholar
• Tobaiqy M, MacLure K, Elkout H, Stewart DThrombotic adverse events reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance databaseVaccines20219111326 1:CAS:528:DC%2BB3MXis1Ogtr3N 10.3390/vaccines9111326 34835256 8624459
   PubMed Web of Science ®Google Scholar
• Heymans S, Cooper LTMyocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanismsNat Rev Cardiol20221927577 1:CAS:528:DC%2BB3MXislajsbfF 10.1038/s41569-021-00662-w 34887571
   PubMed Web of Science ®Google Scholar
• Husby A, Hansen JV, Fosbøl E, et al.SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort studyBMJ2021375 10.1136/bmj-2021-068665 34916207
   PubMedGoogle Scholar
• Focus on myocarditis and pericarditis after COVID-19 mRNA vaccines. 2022. https://www.publichealthontario.ca/-/media/documents/ncov/vaccines/2021/11/myocarditis-pericarditis-mrna-vaccines.pdf?sc_lang=en%20.
   Google Scholar
• Fatima M, Ahmad Cheema H, Huzaifa Ahmed Khan M, Shahid H, Saad Ali M. Development of myocarditis and pericarditis after COVID-19 vaccination in adult population: a systematic review. Ann Med Surg. 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8912977/pdf/main.pdf.
   Google Scholar
• Wong HL, Hu M, Zhou CK, et al.Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databasesLancet20223991034221912199 1:CAS:528:DC%2BB38XhvVSmu7nE 10.1016/S0140-6736(22)00791-7 35691322 9183215
   PubMed Web of Science ®Google Scholar
• Witberg G, Barda N, Hoss S, et al.Myocarditis after Covid-19 vaccination in a large health care organizationN Engl J Med20213852321322139 1:CAS:528:DC%2BB3MXislCntrnL 10.1056/NEJMoa2110737 34614329
   PubMed Web of Science ®Google Scholar
• Das BB, Moskowitz WB, Taylor MB, Palmer AMyocarditis and pericarditis following mRNA COVID-19 vaccination: what do we know so far?Children202187607 10.3390/children8070607 34356586 8305058
   PubMedGoogle Scholar
• Dionne A, Sperotto F, Chamberlain S, et al.Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of childrenJAMA Cardiol202161214461450 10.1001/jamacardio.2021.3471 34374740
   PubMed Web of Science ®Google Scholar
• VAERS—guide to interpreting VAERS data. https://vaers.hhs.gov/data/dataguide.html. Accessed 29 Apr 2022.
   Google Scholar
• Gianfredi V, Pennisi F, Lume A, Ricciardi GE, Minerva M, Riccò M, et al.Challenges and opportunities of mass vaccination centers in COVID-19 times: a rapid review of literatureVaccines202196574 1:CAS:528:DC%2BB3MXitV2rs7nN 10.3390/vaccines9060574 34205891 8230199
   PubMed Web of Science ®Google Scholar